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Abstract Loss of function of p53, either through muta-
tions in the gene or through mutations to other members of
the pathway that inactivate wild-type p53, remains a crit-
ically important aspect of human cancer development. As
such, p53 remains the most commonly mutated gene in
human cancer. For these reasons, pharmacologic activation
of the p53 pathway has been a highly sought after, yet
unachieved goal in developmental therapeutics. Recently
progress has been made not only in the discovery of small
molecules that target wild-type and mutant p53, but also in
the initiation and completion of the first in-human clinical
trials for several of these drugs. Here, we review the cur-
rent literature of drugs that target wild-type and mutant p53
with a focus on small-molecule type compounds. We dis-
cuss common means of drug discovery and group them
according to their common mechanisms of action. Lastly,
we review the current status of the various drugs in the
development process and identify newer areas of p53
tumor biology that may prove therapeutically useful.
Keywords p53  Small molecule compound  Wild-type 
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Introduction
Over the past several decades, anti-cancer drug develop-
ment has witnessed a number of examples of targeted
molecular agents succeed in the clinic. These include i-
matinib for bcr-abl chronic myelogenous leukemia (CML)
and c-kit positive gastrointestinal stromal tumors (GIST),
as well as gefitinib for EGFR mutant tumors [1–3]. While
promising results with these drugs validate the concept of
targeted therapy, the number of patients with these muta-
tions is relatively small compared to the number of patients
with mutations in TP53, RAS, and MYC. These are the most
commonly mutated genes in human cancer, for which there
are no effective targeted drugs available in the clinic today.
Nonetheless, efforts to target these genes therapeutically
remain an area of intense cancer research. With respect to
p53, the field is making progress with several drugs now in
phase I clinical trials and new lead compounds being
developed.
Over 30 years of research on the p53 tumor suppressor
has substantiated it as one of most critically important
genes in human tumor biology [4]. p53 is a transcription
factor whose primary function is to maintain cellular
homeostasis in response to genotoxic stress signals by
different means including upregulation of genes involved
in cell cycle arrest, apoptosis, senescence and metabolism
(Fig. 1) [5, 6]. Given this role, it is obvious why so many
human tumors require the loss of function of p53 to pro-
gress to a fully malignant phenotype. While p53 exhibits
some classical features of a tumor suppressor including loss
of heterozygosity (LOH), it is distinguished by the
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frequency of missense mutations found in the gene. Indeed,
the majority of mutations ([70 %) are single amino acid
missense mutations that generate a defective and abundant
protein. This latter fact is highly important to anti-cancer
drug researchers as it allows p53 to be potentially
targetable.
There are several aspects of the biology of mutant p53
that make it an attractive target for drug development. (1)
The target (mutant p53) protein is found at high levels in
cells. Wild-type p53 protein levels are tightly regulated by
the E3 ubiquitin ligase (MDM2) which targets wild-type
p53 for proteasomal degradation. As an E3 ubiquitin ligase,
MDM2 can also degrade itself as a negative feedback [7].
In cancer cells with mutant p53, this regulation is lost in
part, due to the inability of p53 to transcriptionally
upregulate MDM2 [8, 9], as well as the binding of mutant
p53 to the heat shock protein 90 complex (Hsp90) which
prevents ubiquitination of mutant p53 [10]. (2) Lessons
learned from murine models of cancer indicate that
restoring the function of wild-type p53 in tumors is highly
therapeutic and in some instances curative [11–13]. (3)
There is a growing body of evidence that mutant p53
proteins exhibit a wide range of tumor biology that goes
beyond their loss of wild-type p53 transcriptional function
and collectively has been termed the mutant p53 gain of
function (GOF) phenotype [14]. These proteins have been
implicated in enhanced tumorigenesis, invasion and
metastasis thus targeting them could reap further thera-
peutic rewards [15–18].
While the majority of tumors that have lost the function
of p53 contain missense mutations, there are also a large
proportion of tumors with wild-type p53 that have impaired
p53 signaling due to dysregulated or mutated proteins in
the pathway. Examples of this include increased degrada-
tion of p53 by increased MDM2 activity, which can result
from overexpression of MDM2 in tumors (i.e. MDM2
amplifications) or loss of p19ARF [19, 20]. Alternatively
overexpression of the negative regulator MDMX can result
in a similar effect (impaired p53 signaling) [21]. For this
reason, considerable attention has been given to the
investigation of small-molecules that can increase the
activity of wild-type p53 through targeting MDM2 and/or
MDMX. However, there are still other ways in which p53
signaling is dysregulated that can have an impact on how
agents that target wild-type p53 perform. For example
overexpression of the WIP-1 phosphatase (dephosphoryl-
ates and inactivates p53) through gain of function muta-
tions has been reported as means of inactivating p53 in
human tumors [22].
Here, we review the current research of p53 targeted
drug development focusing on small molecule compounds.
We also provide an overview of current strategies
employed to identify compounds that activate wild-type
p53 and restore wild-type function of mutant p53, as well
as discuss some of their pitfalls and obstacles to clinical
translation. While several other strategies have been
employed to restore p53 function in tumors including the
use of stapled peptides and gene therapeutic approaches
(reviewed in [23, 24]), this review will focus on small
molecules that target wild-type and mutant p53 (Table 1).
Strategies for p53 targeted drug discovery
The pharmacological inhibition or reactivation of tran-
scription factors by small molecules is a challenging task.
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Fig. 1 The p53 pathway. p53 is
a critical responder to various
modes of cellular stress
substantiating its role as a key
tumor suppressor in cancer
biology. These modes serve to
activate p53 both by stabilizing
the protein (decreasing its
MDM2 mediated proteasomal
degradation) and enhancing its
function as a transcription
factor. The response to p53
encompasses a wide range of
cellular processes that allow the
cell to recover/repair the
damage induced by the stress.
The determination of which
effector pathway it uses is
dependent on several variables
including the source of the
stress, the cell type and
surrounding microenvironment
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However, different strategies have been employed to
uncover small molecules that reactivate mutant p53 pro-
teins. These strategies can be divided into a few major
categories based on the readout of the primary screen:
structural stability, trans-activation of p53 targets, growth
inhibition or synthetic lethality.
Reactivation of structural stability
Approximately one-third of p53 mutations result in struc-
turally destabilized proteins [25]. Structure based approa-
ches aim to identify small molecules that stabilize protein
structure. This approach applies x-ray crystal and NMR
structures to identify pockets within the protein that can
serve as templates for which compounds can be designed to
potentially interact. Then in silico screens are performed to
identify small molecules that bind to those pockets and
potentially stabilize the protein structure.
Boeckler et al. [25] screened 2,066,906 compounds to
identify compounds that bind to the p53-Y220C core
domain crystal structure. The Y220C mutation creates a
surface crevice destabilizing the p53 protein [26]. 80 can-
didate compounds were then tested on an in vitro screen to
identify compounds that induce a chemical shift as detected
by NMR spectroscopy. One compound (PhiKan083) was
found to bind to the mutation-induced cleft in Y220C.
Based on the crystal structure of the p53 wild-type DNA
binding domain, molecular dynamics simulations and
genetic studies, Wassman et al. [27] identified the pocket
between loop L1 and sheet S3 of the p53 core domain as a
potential target for small molecules. Subsequently, they in
silico screened 1,324 compounds from the NCI/DTP
chemical repository for the ability to bind to that pocket.
Using this approach they identified stictic acid (NSC87511)
as a candidate p53 reactivating compound. In follow up
validation studies they observed that stictic acid was able to
induce p21 and PUMA in a dose and p53 dependent
manner in Saos-2 p53-null cells transfected with R175H
and G245S relative to untreated controls.
Reactivation of p53 transcriptional activity
The most frequent mutations in p53 result in the change/loss
of wild-type transcriptional activity. Interestingly mutant
p53 retains transcriptional function through both direct and
indirect mechanisms [28]. Nonetheless, reactivation of wild-
type p53 transcriptional activity has been sought as a good
indicator of the success of a chemical screen.
Table 1 Compounds and small molecules that target wild-type and mutant p53
Molecule/compound Mechanism of action Target Stage of development
Activate wild-type p53
Nutlins RG7112
(RO5045337)
Inhibits p53-MDM2 binding MDM2 Phase I clinical trial (NCT01164033,
NCT01143740, NCT00623870 and
NCT00559533) [48]
Benzodiazepinediones
(TDP665759)
Inhibits p53-MDM2 binding MDM2 Preclinical [50]
Spiro-oxindoles (MI-219) Inhibits p53-MDM2 binding MDM2 Preclinical [13]
RITA Inhibits p53 binding p53 (WT and mut) Preclinical [53]
JNJ-26854165
(Serdemetan)
Inhibits p53-MDM2 binding MDM2 Phase I clinical trial (NCT00676910)
[58, 60]
Tenovin 1 and 6 Inhibits SirT1 and SirT2 (protein
deacetylators)
SirT1 and SirT2 Preclinical [117]
SJ-172550 Inhibits p53:MDM2/X binding MDMX Preclinial [69]
RO-2443/RO-5693 Inhibits p53:MDM2/X binding MDMX Preclinical [70]
XI-011 Repression of MDMX promoter MDMX Preclinical [71]
Re-activate mutant p53
CP-31398 Interacts with DNA, reactive oxygen
species
V173A, R175S, R249S, R273H Preclinical [83]
PRIMA-1 (APR-246) Covalently modifies cysteine
residues, protein folding
R273H, R175H Phase I clinical trial (NCT00900614)
[87]
MIRA-1 Alkylation Cysteine and lysine residues R175H, R248 W, R248Q,
R273H, R282W
Preclinical [88]
PhiKan083 Slows thermal denaturation Y220C Preclinical [25]
NSC319726 Zinc chelation/Redox modulation R175H Preclinical [32]
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Wang et al. [29] tested approximately 2,000 compounds
from the NCI/DTP chemical library for their ability to
activate a p53-responsive promoter or cause cell death in
HCT116 p53-null cells. Using this approach they identified
several compounds with the ability to induce p53 target
gene expression, cell cycle arrest and apoptosis in HCT116
p53-null cells. Interestingly, compounds with both p73
dependent and p73 independent activity were identified.
The ability to reactivate p53 target expression was further
validated in vivo using DLD1 (p53-null) tumor xenografts.
Kravchenko et al. [30] screened 46,260 compounds for
their ability to activate p53-response promoters in the A431
cell line bearing a R273H mutant. Using this approach they
identified a small-molecule (reactivation of transcriptional
reporter activity, RETRA) that induced expression of the
p53 homologue, p73 and its release from complex with
mutant p53. Follow up studies showed that RETRA
induced apoptosis in A431 (R273H) cells in a p73 depen-
dent manner and significantly reduced tumor formation in
A431 xenografts.
Reactivation of p53-dependent growth inhibition
Wild-type p53 is activated by a variety of extrinsic and
intrinsic stresses, inducing transcriptional programs that
can lead to cell cycle arrest or apoptosis. When p53 is
mutated p53-dependent growth inhibition is lost. Reacti-
vation of p53-dependent growth inhibition has been also
exploited for chemical screens.
Bykov et al. [31] screened compounds from the NCI/
DTP library for their ability to inhibit growth in several
human tumor cell lines carrying a tetracycline-regulated
R273H or R175H and identified PRIMA-1, a compound
that inhibited growth in a mutant p53 dependent manner.
Follow up validation studies showed that PRIMA-1
restored proper folding of R175H, DNA binding, p53 target
gene expression and induced apoptosis in the cells. In vivo
PRIMA-1 selectively induced apoptosis and reduced tumor
growth of Saos-2 p53-R273H relative to Saos-2 p53-null
mouse xenografts.
We have conducted an in silico screen for compounds
that preferentially inhibit the growth of p53 mutant cells
relative to p53 wild-type cells [32]. Our screen was based
on data from the NCI/DTP anticancer drug screen,
reporting the IC50s for about 50,000 compounds against 60
tumor derived cell lines [33], and the reported p53 status of
those cell lines [34]. A major difference compared with
previous screens is the evaluation of heterogeneous panels
of cell lines rather than engineered isogenic cell lines. This
screen uncovered three thiosemicarbazones which prefer-
entially inhibited p53 mutant cell lines relative to p53 wild-
type cells. One of these compounds, NSC319726, showed
allele specificity against the R175H carrying cells in vitro
and in vivo mouse xenografts. This specificity is in part due
to a refolding of R175H to a wild-type like conformation.
Limitations of screening strategies
Screening methodologies aiming to identify compounds
reactivating a p53 response have caveats and limitations.
Screens based on the transcription of a p53 promoter may
identify compounds that alter the DNA conformation by
intercalating into DNA, resulting in DNA damage [35].
Screens based on a growth inhibition or other phenotypic
assays may identify compounds that do not act directly
through the action of the p53 molecule. Yet, these com-
pounds may still be interesting from the point of view of
synthetic lethality. Compounds aiding the refolding of
structural mutants into a wild-type conformation may still
not be active because they do not trigger the post-transla-
tional modifications that are necessary to obtain a p53
response. From the work reviewed above, it is evident that
these methodologies are tailored for very specific alleles,
including wild-type p53 and different point mutations.
However, the sum of all the methodologies explored so far
does not cover all p53 alleles. The investigation of strate-
gies to identify compounds targeting cancer cells harboring
p53 point mutants that are not classified as DNA binding or
structural mutations is still missing. Furthermore, targeting
p53 null cells requires a different approach altogether,
which can be based on the identification of synthetic
lethality (increased sensitivity to inhibition of another
pathway in the absence of p53) or induction of a p53-like
response by the activation of the p53 family member s p73
or p63 [29].
Targeting wild-type p53
There are two major mechanisms of action for compounds
that increase the activity of wild-type p53 (Fig. 2). The first
involves increasing wild-type p53 levels by interfering
with the MDM2 mediated proteasomal degradation of p53.
The other is through targeting enzymes that negatively
regulate p53 through post-translational modifications. The
p53 protein is under tight regulation by MDM2, an E3
ubiquitin ligase that ubiquitinates p53 and targets it for
proteasomal degradation [36]. MDM2 itself is transcrip-
tionally regulated by p53 which forms a negative feedback
loop allowing for the inhibition of the p53 protein and
subsequent decrease in MDM2 levels [37]. MDM2 is over-
expressed via gene amplification in many human tumors,
which effectively decreases wild-type p53 function [6].
Numerous studies have corroborated the notion that
decreasing MDM2 levels (by various means biochemically
1058 Apoptosis (2014) 19:1055–1068
123
or genetically) leads to an increase in p53 activity [38–41].
As a result considerable efforts have been made by drug
researchers to develop compounds that interfere with the
p53:MDM2 interaction leading to the supposition that
inhibition of MDM2 may lead to re-activation of wild-type
p53 in cancer cells [42].
Targeting the p53:MDM2 interaction has been greatly
benefited by elucidating the x-ray crystal structure of the
amino-terminal domain of MDM2 and a 15 amino acid
peptide sequence of the transactivation domain of p53 [43].
This structure revealed that at the MDM2:p53 interface
there is a well-defined hydrophobic pocket that contacts
three residues on p53 (Phe19, Trp23 and Leu26) that could
potentially be the target of a small molecule inhibitor [44].
The nutlins, benzodiazepinediones and spiro-oxindoles are
three groups of small molecules that have been found
through a variety of chemical screens to bind to MDM2
and prevent p53 binding.
Nutlins
Nutlins are a group of cis-imidazoline small-molecule
compounds identified from a large chemical screen and
chosen for their potency and selectivity for inhibition of the
MDM2:p53 interaction, with IC50 values from 100 to
300 nM [45]. Nutlin-3a, when used at micromolar con-
centrations, arrested proliferating cancer cells in the G1
and G2 cell cycle phases as well as induced apoptosis in
wild-type p53 dependent manner, in a number of different
cancer cell lines including colorectal, lung, breast, prostate,
melanoma, osteosarcoma and renal cancer, all of which
expressed wild-type p53 when studied by Tovar et al. [46].
Every cell line treated with Nutlin-3a demonstrated dose
dependent p21 induction and cell cycle arrest [46]. For
reasons pertaining to pharmacologic properties of Nutlin-
3a, further lead optimization was required to generate a
compound for clinical development. RG7112 is a potent
and selective member of the nutlin family that has been
optimized pharmacologically and can be given orally [47].
It has been shown in human xenograft models to inhibit
wild-type p53 tumor growth in a dose dependent fashion
and even exhibited regression in some instances. RG7112
(RO5045337) is currently in phase-I clinical trials
(NCT01164033, NCT01143740, NCT00623870, and
NCT00559533) in advanced solid tumors, hematologic
malignancies and liposarcomas and was shown to be well
tolerated and demonstrating some clinical activity [48].
Benzodiazepinediones
The Benzodiazepinediones are benzodiazepine derivatives
that disrupt the MDM2:p53 interaction in a similar manner
to the nutlins by mimicking the action of the key amino
acids involved in the binding of the p53 peptide to MDM2
[49]. The compounds that interacted with MDM2 were
identified when screening of a library of 22,000 benzodi-
azepinediones. The compounds that bound to MDM2 were
identified by their increased thermal stability using Ther-
moFluor microcalorimetry to monitor temperature depen-
dent protein folding [50]. The benzodiazepinedione
compound TDP665759 was found to bind to MDM2 with
an IC50 of 704 nM and inhibit proliferation in cell lines
expressing wild-type p53 [50].
Spiro-oxindoles
The spiro-oxindoles are small molecule MDM2 inhibitors
designed via computational modeling to activate wild-type
p53 by mimicking the p53 amino acid side-chains which
interact with the MDM2 binding pocket [49]. Ding et al.
[44] determined that the indole ring of the Trp23 amino
acid residue was vital for p53 to fit into the hydrophobic
pocket of MDM2 and thus developed oxindole based small
molecules that could mimic this interaction. An advantage
of the spiro-oxindoles is that they have specificity against
cancer cell lines versus normal epithelial cells [44]. One of
these compounds, MI-219, has been shown to inhibit
cancer cell proliferation and to inhibit tumor growth in
MDM2
MDMX
p53
P P
Ac
P
Nutlins (Nutlin 3a, RG7112)
Benzodiazepinediones (TDP665759)
Spiro-oxindoles (MI-219)
Serdemetan (JNJ-26854165)
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SJ-172550 
indolyl hydantoin compounds 
(RO-2443 and RO-5693) 
XI-011 (NSC146109) 
SirT1
SirT2
Deacetylation
Tenovin 1 and 6
Fig. 2 Mechanisms of action for drugs that target wild-type p53—a
number of compounds now exist that serve to enhance the function of
wild-type p53 by increasing the stability of p53 through various
mechanisms: The largest group (nutlins, benzodiazepinediones and
spiro-oxindoles) serve to increase the stability of p53 by targeting the
MDM2:p53 interaction. This leads to decreased MDM2 mediated
proteasomal degradation of p53. MDMX inhibitors block the
MDMX-p53 interaction so as to activate wild-type p53. RITA also
stabilizes wild-type p53 supposedly through binding p53 and inducing
a conformational change that disrupts the p53:MDM2 binding, though
this is controversial. Other compounds (tenovins) enhance the
stability of p53 through inhibition of the sirtuins
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xenograft models. It also has good tissue bioavailability in
mice and is orally active [51, 52].
Reactivation of p53 and induction of tumor cell
apoptosis (RITA)
RITA is a compound identified via phenotypic screen using
isogenic colon cancer cell lines HCT116 (wild-type p53 vs.
null). Using a cell proliferation assay, compounds from a
National Cancer Institute (NCI) database were tested to
assess whether they suppressed the growth of the wild-type
cell line [53]. Using fluorescence anisotropic experiments,
it was shown that RITA directly binds p53 and causes a
conformational change that prevents the binding between
p53 and MDM2, effectively inducing apoptosis in cells
with wild-type p53, but not mutant p53 or null. Moreover,
RITA has been shown to inhibit p53-wild-type xenograft
tumor growth when administered intra-peritoneally. How-
ever, the exact mechanism that RITA uses to activate wild-
type p53 remains unclear. Recently heteronuclear single-
quantum coherence (HSQC) NMR was used to determine if
RITA bound p53 in vitro. 15-N-labeled MDM2 (118 amino
acid N-terminal domain) and p53 (312 amino acid N-ter-
minal domain and DNA binding domains) fragments were
synthesized and NMR spectra produced. RITA could not
displace MDM2 binding in these experiments leading to
the conclusion that RITA does not bind the N-terminus of
p53 [54]. An alternative mechanism for RITA mediated
p53 activation in multiple myeloma cells was recently
described in which RITA transcriptionally induced p53 by
activating JNK signaling which as its downstream effects
leads to increased c-jun binding to the AP-1 binding sites in
the p53 promoter. In these experiments inhibiting JNK
signaling through an si-RNA to JNK inhibited RITA
mediated p53 activation [55].
RITA has since also been found to suppress growth in a
number of different cancers with mutant p53 such as colon,
lung and breast carcinoma as well as Burkitt lymphoma
with mutations at residues—273, 175 and 248, 280, 213,
234, 283, 254 and 125 [56]. RITA was shown to induce
apoptosis in these mutant cell lines as well as transcrip-
tionally activate p53 targets p21, BAX, Noxa and PUMA
[56]. It is not clear how RITA can activate both wild-type
and mutant p53. Nonetheless, RITA has been studied in
combination with other drugs such as cisplatin where RITA
enhanced cisplatin cytotoxicity through upregulation of
p53 downstream apoptotic targets in head and neck cancer
cells [57].
JNJ-26854165 (Serdemetan)
JNJ-26854165 (Serdemetan) is a p53 activating tryptamine
derivative that was initially thought to activate wild-type
p53 by functioning as a E3 ubiquitin ligase inhibitor [7].
Kojima et al. [58] found that Serdemetan induced p53
dependent apoptosis and transcriptional activation of p21
and Noxa in a number of leukemia cell lines. It was also
found to induce early apoptosis (48 h) in cells with wild-
type p53 status and delayed apoptosis (72–96 h) in mutant
p53 cell lines [58]. Other pre-clinical studies have also
found activity in both wild-type and mutant p53 tumors
indicating that the mechanism involves both p53 dependent
and independent functions [59]. Chargari et al. [60] found
that Serdemetan significantly enhanced radiation induced
growth delay in wild-type (H460 cell line) xenograft
tumors as well as demonstrating G2/M cell cycle arrest in
H460 and A549 cell lines.
Serdemetan was tested in a Phase I clinical trial in 5
study centers in Belgium and Spain in patients with
advanced refractory solid malignancies (mostly colorectal
cancers, sarcomas and melanomas). Serdemetan was found
to be rapidly absorbed orally and maximum tumor reduc-
tion was seen in patients receiving above 150 mg/day, the
threshold for induction of p53 in skin biopsies [61]. This
compound is no longer in clinical development.
MDMX inhibitors
MDMX is a partner protein to MDM2 that is structurally
similar at the N-terminal domain where both proteins bind
p53 [62]. While MDMX has no intrinsic E3 ubiquitin
ligase activity, it does dimerize with MDM2 and MDM2/
MDMX heterodimers not only enhance ligase activity but
also are responsible for the polyubiquitination of p53
whereas MDM2 alone monoubiquitinates p53 [63, 64].
Genetic experiments in mice have demonstrated the
importance of these MDM2/MDMX heterodimers in the
negative regulation of p53 [65]. Owing to differences in the
p53 binding sites between MDM2 and MDMX, MDM2
antagonists like Nutlin-3 have low affinity for MDMX and
thus their ability to maximally inhibit p53 is diminished
particularly in tumors where MDMX is over-expressed [66,
67]. This understanding has lead to the search for small
molecules that inhibit MDMX as a means of activating p53
more robustly. Proof of this concept was recently demon-
strated where a 12-mer peptide was identified that inhibited
both the MDM2:p53 and MDMX:p53 interactions [68]. In
cell lines over-expressing MDMX, this peptide demon-
strated superior cell growth inhibition over Nutlin-3a.
Since then several small molecules have been reported to
activate wild-type p53 through targeting MDMX.
The first small molecule reported was SJ-172550, which
was identified through a peptide-based high throughput
screen and validated to kill cells over-expressing MDMX
by reversibly binding MDMX [69]. These effects were
found to be additive when SJ-172550 was administered
1060 Apoptosis (2014) 19:1055–1068
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in vitro with Nutlin-3a. Most recently, a series of indolyl
hydantoin compounds RO-2443 and RO-5693 were also
described as potent inhibitors of MDMX by binding to the
p53 pocket of MDMX and inducing protein dimerization.
RO-5693 activated wild-type p53 in a non-genotoxic
fashion and was able to overcome the resistance of MDMX
over-expressing cancer cells to Nutlin-3a [70]. Lastly
another compound XI-011 (NSC146109) was reported to
activate wild-type p53 in breast cancer cells by a mecha-
nism that involved inhibition of MDMX through tran-
scriptional repression of the MDMX promoter [71]. These
compounds are all still very early in the development
process but certainly validate the concept that MDMX
blockade can overcome the limitations of MDM2 antago-
nists particularly in MDMX over-expressing tumors.
Tenovin 1 and Tenovin 6
Tenovins belong to the group of compounds that activate
wild-type p53 indirectly through targeting enzymes
involved in negative regulation of p53. These are Sirtuins
(such as SirT1 and Sir T2), a family of protein deacety-
lating enzymes. SirT1 has been shown to destabilize p53 by
deacetylating one of its carboxy-terminal lysines (Lys382)
which may lead to ubiquitination and proteasomal degra-
dation [23]. Using a cell based screen, Tenovin 1 was
identified to inhibit sirtuins activity [72]. A secondary
compound Tenovin-6 is seven times more water soluble
and is more cytotoxic. Tenovin 6 has also been shown to
decrease tumor growth in vivo [23].
Obstacles to clinical translation
There are several considerations that have still yet been
resolved concerning the application of small molecule
compounds that activate wild-type p53. One needs to
consider the effect of activating wild-type p53 in normal
non-cancerous tissues which could theoretically be toxic.
Previous experiments of whole body radiation to mice as a
means of activating p53 confirmed that the response to
radiation is tissue specific with proliferative tissues being
affected most significantly [73], thus bone marrow and
intestinal toxicities are of concern with these drugs. The
effect of activating p53 in normal tissues has been studied
using mice carrying a hypomorphic allele of MDM2. These
mice displayed a phenotype that was characterized by
increased apoptosis in lymphocytes and epithelial cells that
was p53 dependent [74]. This allele did not affect their
development or lifespan but did affect their size. Thus it
remains to be seen if these toxicities will also be found in
patients as phase 1 testing of MDM2 antagonists is cur-
rently underway. It may be possible to mitigate these
toxicities by administering p53 modulating drugs in com-
bination with other therapies which would allow the
administration of a lower dose of the p53 modulating agent
[75, 76]. Another potential obstacle to the translation of
activators of wild-type p53 is the acquisition of mutations
in p53 during treatment. While it is known that genotoxic
stress to cells with ionizing radiation or cytotoxic chemo-
therapy can induce mutations in p53, it was thought that
this would not be an issue with MDM2 antagonists. Maki
group recently demonstrated that treating wild-type p53
cancer cells chronically with Nutlin-3a could lead to
resistant clones that acquired p53 mutations [77]. Nearly
one-fifth of breast, colon and lung cancers over-express
MDMX which is also a potential obstacle to the develop-
ment of MDM2 inhibitors such as Nutlin-3a [21].
It is also possible that activation of p53 in tumor cells
could lead to a senescence phenotype that might be prob-
lematic in the long term. Several laboratories have reported
that the primary response in human tumor cells with wild-
type p53 to genotoxic chemotherapeutic agents is not
apoptosis but a form of stress induced premature senes-
cence (SIPS) [78]. This could be problematic as these cells
could escape this senescence and re-enter the cell cycle.
The mechanisms that govern an apoptotic versus senes-
cence p53 mediated phenotypes need to be further explored
as these will impact the response to p53 targeted agents.
Evidence that tissue specificity plays a role was reported
when p53 expression was restored in a genetically engi-
neered mouse model of Li-Fraumeni syndrome. Restora-
tion of p53 function lead to apoptosis in lymphomas and
senescence in sarcomas [12]. Lastly, a barrier to successful
clinical translation for many targeted molecular agents is
identifying additional drugs that can be used in combina-
tion to enhance efficacy. With respect to MDM2 inhibitors
clues to which drugs to combine have revealed several
candidates including cyclin dependent kinase inhibitors as
well as adenoviral p53 mediated gene therapy [76, 79].
Restoration of wild-type function of mutant p53
Eighty-one percent of the mutations in human tumors
which have lost wild-type p53 function are missense
mutations [80]. These mutations have been extensively
characterized by the International Agency on Cancer
Research (IARC) [81]. The vast majority (95 %) of these
mutations occur within the DNA binding domain of p53
with six (hotspot) mutations occurring with a particularly
high frequency [81]. These point mutations of p53 can be
classified as either DNA contact or structural/conforma-
tional mutations. Contact mutations (such as those occur-
ring at amino acids R273H and R248Q) have very little
effect on the ability of the p53 protein to fold and therefore
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are very similar structurally to wild-type p53. On the other
hand, structural mutations (such as R175H and R249S)
have a significant effect on protein folding causing desta-
bilization of the protein structure [37, 82]. Moreover, some
point mutations are identified. These distinctions are
important as we gain a greater appreciation for the phe-
notypic differences that these proteins impart to tumor cells
as well as the fact that newer p53 mutant reactivators have
exhibited allele specific effects.
CP-31398
CP-31398 is a styrylquinazoline synthetic small molecule
discovered in an in vitro assay by Pfizer that screened for
molecules that protected the p53 core domain from dena-
turation upon application of heat [83, 84]. CP-31398 has
been shown to increase expression of wild-type p53 targets,
such as p21, when interacting with different p53 mutants
such as 173 or 249 mutants in an Saos-2 osteosarcoma cell
line [83]. In immunoblot experiments using a p53 null lung
cancer cell transfected with mutant p53 (173 mutation),
low micromolar concentrations of CP-31398 were found to
increase PAB1620 (wild-type antibody) positive cells by
five-fold after treatment for 6 h [83]. In mouse xenografts,
twice daily injections of CP-31398 was found to com-
pletely inhibit growth of the colon tumor (241 mutation)
and decreased tumor growth of melanoma cell line (249
mutation) by 75 % [83].
This compound was found to be initially promising;
however Rippin et al. [85] determined by florescence
experiments that CP-31398 intercalated into free DNA and
remained bound when DNA complexed with p53, but had
no detectable binding to the wild-type or R249S p53 core
domain with concentrations up to 3 mM and concluded
that this drug suppressed tumor cell growth in a p53
independent manner, likely due to its ability to intercalate
into DNA [85].
p53 reactivation and induction of massive apoptosis
(PRIMA-1)
PRIMA-1 and its metabolite APR-246, have advanced the
furthest in the drug development process amongst the drugs
that target mutant p53. PRIMA-1 was identified by a
chemical screen of an NCI chemical library that inhibited
the growth of an osteosarcoma cell line (Saos-2) that car-
ried a tetracycline-regulated mutant p53 (R273H) but had
minor growth rate inhibition in tumor lines absent of
mutant p53 (wild-type and null) [31].
Immunofluorescence experiments using conformation
specific antibodies PAB1620 (recognizing wild-type con-
formation) and PAB240 (recognizing mutant conforma-
tion) showed an increase in wild-type conformation and a
decrease in mutant conformation after treatment, indicating
that PRIMA-1 induced a ‘‘wild-type’’ like conformation
change to the p53-R175H mutant. This group also deter-
mined that PRIMA-1 could restore DNA binding in elec-
tromobility shift assays to a wide array of mutants that
included both DNA contact (R248, R273) and conforma-
tional mutants (R175H) [31].
In a follow-up study by this group, Lambert et al. [86]
reported on the mechanism of action of PRIMA-1. They
determined that one of the decomposition products of
PRIMA-1/PRIMA-1MET has a chemically active double
bond to covalently react with thiol groups in mutant p53.
This was demonstrated with the addition of NAC that
inhibited PRIMA-1 dependent apoptosis and growth sup-
pression. Furthermore, it was suggested that PRIMA-1MET
induced oxidation in mutant p53 cells may contribute to its
effects.
The first in-human clinical trial of a drug that targets
mutant p53 was reported using APR-246 in 22 patients
with hematologic malignancies and hormone refractory
prostate cancer examining maximum tolerated dose
(MTD), safety and pharmacokinetics [87]. This study used
a standard dose-escalation scheme in which 3 patients were
treated with each incremental dose using doses of 2, 3, 10,
30, 60 and 90 mg/kg. If no dose limiting toxicity (DLT)
was observed then patients were treated with the next
higher dose. If there was a DLT in one of the three patients,
then the next group would be treated with the same dose.
Overall there were 12 adverse events that were judged to be
related to the study drug. The most common adverse events
were fatigue, confusion, muscle aches, and sensory dis-
turbances. These typically occurred during or near the end
of the infusion and all were reversible with no bone mar-
row toxicity seen.
Pharmacokinetic studies demonstrated a plasma half-life
of 4–5 h. Pharmacodynamic studies were performed on a
limited number of patients with hematologic malignancies
as they could sample circulating tumor cells before and
after treatment. They performed cell-cycle, apoptosis and
gene expression measurements for p53 downstream target
genes on the circulating tumor cells. Three of twelve
analyzed samples had p53 gene mutations with the
remaining samples having wild-type status. The increase in
p53 activity did not appear to correlate with p53 mutational
status and further assessment of APR-246 needs to be made
to assess its ability as a mutant reactivator [87].
Mutant p53-dependent induction of rapid apoptosis
(MIRA-1)
MIRA-1 is a maleimide derived molecule identified along
with PRIMA-1 in a cellular screen. It appears to reactivate
and restore apoptotic activity to mutant p53 (at residues
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R175H and R273H) by increasing DNA fragmentation and
inducing caspase activity [82, 88]. Bykov et al. [88]
demonstrated that MIRA-1 preserved the native confor-
mation of both wild-type and mutant p53 (R175H and
R248W) upon heating and also preserved sequence-specific
DNA binding (R175H, R282W, R248Q, R248W/C176Y).
MIRA-1 and its analog MIRA-3 were able to induce acti-
vation of target genes p21, MDM2 and PUMA which was
mutant p53 dependent [88].
PhiKan083
PhiKan083 is a carbazole derivative that binds to a surface
cavity created by the conformational mutation Y220C
which highly destabilizes the p53 protein by 4 kcal/mol
[25]. PhiKan083 was discovered via an in silico screen of
the ZINC database based on its crystal structure and NMR
spectroscopy and was shown to bind to the target surface
crevice and raise the apparent melting temperature of the
Y220C mutant by almost 2 C, slowing its rate of thermal
denaturation and increasing its half-life from 3.8 to
15.7 min [25, 89]. Most recently, PK7088 was found to
change the Y220C conformation mutation and reactivate
this mutant [90].
Thiosemicarbazones
Several members of the thiosemicarbazone family were
identified by an in silico screen of the NCI60 anti-cancer
drug screen (NSC319725, NSC319726, NSC328784) as
compounds that had preferential activity in mutant p53
cells lines while displaying relatively little toxicity in cell
lines containing wild-type p53. Two of these compounds
(NSC319725 and NSC319726) were validated and dis-
played increased sensitivity in cell lines expressing the
p53-R175H mutant. Further study of NSC319726 (726)
indicated that this compound induced apoptosis in R175H
cells by restoring wild-type structure and function this
mutant at doses that were completely nontoxic to normal
human fibroblasts. Interestingly, this compound did not
reactivate the contact mutants R248 or R273, thus dis-
playing allele-specific p53 mutant reactivation. 726 inhib-
ited xenograft tumor growth in mice that was R175H
mutant dependent at relatively small doses of the drug (1
and 0.1 mg/kg) [32].
The mechanism of 726’s apparent R175H specific
mutant p53 reactivational effects is currently unknown.
There are some initial clues to the mechanism as it was
found that the compound depends upon its zinc chelating
and reactive oxygen species (ROS) inducing properties
[32]. Supplemental zinc added to the media of R175H cells
enhances the apoptotic effect of 726. Given that the R175H
mutant is known as a ‘‘zinc-binding’’ mutant because this
mutation impairs the protein’s ability to bind zinc, it is
hypothesized that this compound may act as a zinc me-
tallochaperone by donating zinc to allow this mutant to
refold properly. Other groups have even demonstrated that
supplemental zinc alone can induce such a conformational
change in p53-R175H mutant cells [91]. Nonetheless, if
726 indeed functions as a zinc metallochaperone, it may
also reactivate other mutants with impaired zinc binding.
Thiosemicarbazones have shown to induce ROS chan-
ges in cells by the creation of hydroxyl radicals through
Fenton Chemistry [92]. Consistent with this, 726 was found
to induce ROS levels in R175H mutant cells by measure-
ments of the natural cellular dextoxificant, glutathione.
Indeed these ROS changes induced by 726 are important to
its mechanism as treatment with the detoxifying drug
N-acetyl cysteine (NAC) abrograted much of the apoptotic
activity of 726 in R175H mutant cells [32]. The exact role
that these ROS changes play in the mechanism of 726 is
currently unknown.
Heat shock protein 90 inhibitors
It is well known that mutant p53 protein levels are high in
cancer cells. This had been previously attributed to a loss
p53 mediated transactivation of MDM2 [8, 9]. Recently, it
has been demonstrated using p53 knock-in missense
mutant mice that mutant p53 is degraded in an MDM2
mediated fashion in non-tumor tissues, and in a subset of
tumor tissues indicating that other mechanisms are
involved in stabilizing mutant p53 [93]. Once such mech-
anism that has been elucidated is the binding of mutant p53
to heat shock protein 90 (Hsp90) which serves to protect
mutant p53 from ubiquitination. Knock-down of HSP90 or
pharmacologic inhibition with 17-allylamino-17-deme-
thoxygeldanamycin (17-AAG) resulted in a release of
Hsp90 from mutant p53 bound to MDM2 allowing ubiq-
uitination and degradation [10]. Thus HSP90 inhibition
theoretically might help reverse the mutant p53 gain-of-
function phenotype (GOF) attributed to mutant p53.
p53 and metabolism
Another emerging and exciting area of p53 research that
has important implications for wild-type and mutant p53
targeted drug development is the role that p53 plays in the
regulation of metabolism. It is now well known that the
metabolism of cancer cells is altered in ways that provide a
selective advantage for tumor progression and tumor
maintenance [94, 95]. This includes alterations in glucose
metabolism that favor anaerobic glycolysis (otherwise
known as the Warburg effect), decreased mitochondrial
respiration, and increased glutaminolysis to assist in both
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the replenishment of non-essential amino acids as well as
in providing a carbon source for the synthesis of macro-
molecules (anaplerosis) [96]. This metabolic reprogram-
ming is necessary for cancer cells to overcome both
internal and external sources stress that would arrest or
induce apoptosis in non-transformed cells. This metabolic
transformation not only comes about as a response of the
cell to changes in the extracellular environment (i.e.
hypoxia), but also as a direct result of oncogene activation
and/or loss of tumor suppressor function such as p53 [95].
How p53 functions as a tumor suppressor has largely
been attributed to its role in mechanisms of cell cycle
arrest, apoptosis and senescence. However, this concept
has been recently challenged by several studies that taken
collectively argue that p53’s tumor suppressive properties
are likely mediated by other functions of p53. For example,
mice lacking either PUMA, NOXA or p21 which are
downstream of p53 in mediating both apoptosis, and cell
cycle arrest fail to develop spontaneous tumors [97, 98].
Gu et al. recently generated p53 mutant mice with three
lysine to arginine mutations at three positions in the DNA
binding domain important for regulation of p53 by post-
translational acetylation. These three mutations abated
p53’s ability to regulate cell cycle arrest, apoptosis or
senescence. Intriguingly these mice did not succumb to
early onset tumor formation as did p53 null mice indicating
that tumor suppression must be mediated by other p53
functions. When they interrogated the metabolic functions
of this mutant, they found that this mutant could still reg-
ulate metabolic target genes such as glutaminase-2 and 3,
and TP53-induced glycolysis and apoptosis regulator
(TIGAR) as well as genes involved in the regulation of
reactive oxygen species indicating that metabolic regula-
tion may be one function of p53 that is involved in tumor
suppression [99]. Exactly how p53 exerts its tumor sup-
pression through its regulation of metabolism is not yet
clear, but some emerging areas of research in p53 and
metabolism point to several directions that potentially
could impact developmental therapeutics.
One area focuses on the role that p53 plays in sup-
pressing geroconversion [100]. Geroconversion is named
for its relationship to the senescent or aging phenotype and
is defined as the conversion from a reversible state of
senescence (quiescence) to a state of irreversible senes-
cence. This phenotype is thought to be pro-tumorigenic as
these cells are hypertrophic, hypersecretory, hypermeta-
bolic and hyper-inflammatory [101]. By suppressing
geroconversion, p53 promotes quiescence which is char-
acterized by a state of low protein synthesis, and metabo-
lism. Signaling through the phosphoinositide 3-kinase
(PI3K)/mammalian target of rapamycin (mTOR) pathway
is thought to promote geroconversion and highlights the
general reciprocal roles that the p53 and the mTOR
signaling pathways play in the regulation of cell growth.
TP53 negatively regulates the mTOR pathway through a
number of means [102–104]. For example, it activates
AMP-activated protein kinase (AMPK) by upregulating the
sestrins in addition to upregulating a number of genes that
negatively regulate the mTORC1 complex [105]. The
PI3K/mTOR pathway is activated in large number of
cancers which provides a rationale for the combination of a
p53 modulating drug and an mTOR inhibitor [78, 106,
107].
Another area is p53’s regulation of the cellular processes
that bioenergetics and macromolecular synthesis. It is here
that p53 acts in a number of locations to influence these
reactions through regulation of transcriptional targets. In
general p53 functions to slow down glycolysis and speed
up oxidative phosphorylation in essence opposing the
Warburg effect [108, 109]. This is accomplished in part
through activation of targets such as TIGAR (inhibits
glycolysis through decreasing levels of fructose 2, 6-bis-
phosphate) and synthesis of cytochrome c oxidase (SCO2)
(increases oxidative phosphorylation through SCO2 pro-
tein) [110]. By decreasing glycolysis, TIGAR allows glu-
cose intermediates to be shunted through the Pentose
Phosphate Pathway (PPP), which is essential for anti-oxi-
dant function through the production of NADPH and
reduced glutathione. While it is tempting to speculate that
p53’s tumor suppressive function may be in part mediated
through TIGAR, recent studies of the role of TIGAR in
tumor formation have not supported this. Recently the
function of TIGAR was studied by genetic deletion in a
mouse model of intestinal adenoma formation [111]. In this
model the absence of TIGAR leads to a decrease in tumor
formation which may indicate that suppression of ROS
may be necessary during early tumorigenesis. This illus-
trates the need for further research in understanding how
p53’s role in metabolic reprogramming functions in tumor
suppression.
Nonetheless, through our current understanding of the
role of p53 in metabolic reprogramming, we can now begin
to appreciate how this may exploited therapeutically. For
example, the Pentose Phosphate Pathway (PPP) which
among other things is a major mechanism for the cell to
provide a renewed source of NADPH that is essential for
regulating the redox state of cellular glutathione (GSH) and
its oxidized form (GSSG) [112]. Without proper GSH
levels, cells are vulnerable to an ROS mediated cell death.
An example of this was illustrated recently in an elegant set
of experiments in which the metabolic adaptations to serine
starvation were studied in cancer cells with and without
functional p53 [113]. Serine starvation of cancer cells
caused them to shunt glucose from the glycolytic pathway
towards the serine the biosynthesis pathway. This leads to
an increase in flux through the tricarboxylic acid (TCA)
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cycle and hence an increased production of ROS. Impor-
tantly, p53 wild-type cells responded to this by maintaining
production of cellular GSH synthesis while p53 deficient
cells displayed reduced GSH. This critical difference
caused the p53 deficient cells to undergo an ROS mediated
cell death. This could represent an ‘‘Achilles heel’’ for
cancer cells that lose p53 function by using drugs that
mimic serine starvation, inhibit the PPP, or perhaps shunt
the flux of glucose through the TCA cycle to take advan-
tage of similar mechanisms to produce an anti-cancer
effect. This concept has also been illustrated with the drug
Metformin. Metformin activates AMPK which in turn can
activate p53 (AMPK phosphorylates p53 on serine-15). In
cells with functional p53, this results in a number of met-
abolic changes in the cell that among other things, induce
autophagy. When tumor cells lack p53, this induction of
autophagy does not occur and cells succumb to apoptosis
[114].
Another role for p53 in cancer metabolism that might be
relevant to drug development is the control of oxidative
stress. Here the role for p53 is dual and seemingly opposing
which seems to be related to the levels of p53. In situations of
normal cellular function, basal levels of p53 control the
transcription of several anti-oxidant genes (sestrin 1
(SESN1), sestrin 2 (SESN2), glutathione peroxidase 1
(GPX1)), which function to regulate the ROS that is pro-
duced by normal cellular respiration. Recently, the enzyme
glutaminase-2 was found to be a p53 transcriptional target
that serves to lower redox levels through the generation of
GSH from glutamine [115]. In situations of significant stress,
p53 can increase ROS levels through the transcription of a
number of pro-oxidant genes such as PUMA, NOXA, and
NQO1 and carry out an apoptotic program (reviewed in
[112]). It is this latter finding that may be relevant to mutant
p53 targeted drug development because in mutant p53 can-
cer cells, the levels of the mutant protein are high. This may
help trigger a pro-oxidant function in p53 upon application
of a mutant p53 reactivating drug. This was demonstrated for
the p53 reactivating thiosemicarbazone NSC319726 [32].
Conclusion
Over three decades of research on p53 has substantiated it as
one of the most critical cancer genes in human tumor biology
uncovering an enormous potential for therapeutic activity.
Yet we still today have not translated these findings into any
approved p53 targeted agents. This has led some to question
whether p53 targeted therapies represent an ‘‘empty prom-
ise’’ [116]. At this time, one cannot make this conclusion as
there is clearly evidence of progress in the field. We now
have agents that target wild-type p53 and mutant p53 in
human clinical trials for the first time. It is important to be
reminded that the drugs that are being tested in these clinical
trials were based off of lead compounds that were discov-
ered in the last 10 years [31, 45]. Moreover, new compounds
have been identified for pre-clinical development as well as
novel strategies for drug discovery. Some of these com-
pounds employ mechanisms of action that contain clues to
restore the function of wild-type p53 in additional p53 miss-
sense mutants and thus require more investigation. Further
study of combination therapies (e.g., involving conventional
cytotoxic agents, or targeted agents such as mTOR inhibi-
tors, administered in combination with p53 modulators) is
also needed as these may overcome issues pertaining to
toxicity and efficacy of p53 modulator monotherapy. Cer-
tainly, newer areas of p53 research such as stem cell biology,
cancer metabolism and p53 mediated micro-RNA regulation
will no doubt impact the field of p53 targeted therapy. In an
era of personalized medicine, it will likely be important to
design innovative clinical trials that are ‘‘proof of concept’’
type studies that enroll patients based on their p53 muta-
tional status to continue to advance the field.
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